{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:38:26Z","timestamp":1761154706682},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1994,1,1]],"date-time":"1994-01-01T00:00:00Z","timestamp":757382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Tr"],"published-print":{"date-parts":[[1994]]},"DOI":"10.1007\/bf00689672","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T03:32:52Z","timestamp":1101699172000},"page":"5-9","source":"Crossref","is-referenced-by-count":65,"title":["Alternative mechanisms of action of anti-oestrogens"],"prefix":"10.1007","volume":"31","author":[{"given":"Anthony A.","family":"Colletta","sequence":"first","affiliation":[]},{"given":"John R.","family":"Benson","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Baum","sequence":"additional","affiliation":[]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1126\/science.3283939","volume":"240","author":"RM Evans","year":"1988","unstructured":"Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889?895, 1988","journal-title":"Science"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0955-0674(89)90012-4","volume":"1","author":"J Ham","year":"1989","unstructured":"Ham J, Parker MG: Regulation of gene expression by nuclear hormone receptors. Curr Opinion Cell Biol 1: 503?511, 1989","journal-title":"Curr Opinion Cell Biol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0168-9525(88)90108-4","volume":"4","author":"S Green","year":"1988","unstructured":"Green S, Chambon P: Nuclear receptors enhance our understanding of transcriptional regulation. Trends Genet 4: 309?314, 1988","journal-title":"Trends Genet"},{"key":"CR4","first-page":"317","volume":"42","author":"E Coezy","year":"1982","unstructured":"Coezy E, Borgna JL, Rochefort H: Tamoxifen and metabolites in MCF-7 cells: correlation between binding to oestrogen receptor and inhibition of cell growth. Cancer Res 42: 317?323, 1982","journal-title":"Cancer Res"},{"key":"CR5","first-page":"15","volume-title":"Nuclear Hormone Receptors 2","author":"S Green","year":"1991","unstructured":"Green S, Chambon P: The oestrogen receptor: from perception to mechanism. In: Parker MG (ed) Nuclear Hormone Receptors 2. Academic Press, London, 1991, pp 15?34"},{"key":"CR6","first-page":"3998","volume":"43","author":"RL Sutherland","year":"1983","unstructured":"Sutherland RL, Hall RE, Taylor IW: Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effect of tamoxifen on exponentially growing and plateau phase cells. Cancer Res 43: 3998?4006, 1983","journal-title":"Cancer Res"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0006-291X(86)90763-1","volume":"140","author":"RL Sutherland","year":"1986","unstructured":"Sutherland RL, Watts CKW, Reunitz PC: Definition of two distinct mechanisms of action of antioestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the oestrogen receptor. Biochem Biophys Res Comm 140: 523?529, 1986","journal-title":"Biochem Biophys Res Comm"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/288273a0","volume":"288","author":"RL Sutherland","year":"1980","unstructured":"Sutherland RL, Murphy LC, Ming San Foo, Green MD, Whybourne AN: High affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature 288: 273?275, 1980","journal-title":"Nature"},{"key":"CR9","first-page":"2462","volume":"45","author":"CA O'Brian","year":"1985","unstructured":"O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462?2465, 1985","journal-title":"Cancer Res"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/312315a0","volume":"312","author":"MJ Berridge","year":"1984","unstructured":"Berridge MJ, Irving RF: Inositol triphosphate, a novel second messenger in cellular signal transduction. Nature 312: 315?321, 1984","journal-title":"Nature"},{"key":"CR11","first-page":"1243","volume":"76","author":"CA O'Brian","year":"1986","unstructured":"O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB: Triphenylethylenes: A new class of Protein Kinase C inhibitors. J Natl Cancer Inst 76: 1243?1246, 1986","journal-title":"J Natl Cancer Inst"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1016\/0006-2952(85)90225-4","volume":"34","author":"H-D Su","year":"1985","unstructured":"Su H-D, Mazzei GJ, Vogler WR, Kuo JF: Effect of tamoxifen, a non-steroidal antioestrogen, on phospholipid\/calcium dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain ovary. Biochem Pharmacol 34: 3649?3653, 1985","journal-title":"Biochem Pharmacol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0006-291X(84)91062-3","volume":"118","author":"H-YP Lam","year":"1984","unstructured":"Lam H-YP: Tamoxifen is a calmodulin antagonist in the activation of a cAMP phosphodiesterase. Biochem Biophys Res Comm 118: 27?32, 1984","journal-title":"Biochem Biophys Res Comm"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0006-2952(90)90689-I","volume":"40","author":"MG Rowland","year":"1990","unstructured":"Rowland MG, Parr IB, MacCague R, Jarman M, Goddard PM: Variation of the inhibition of calmodulin dependent cyclic AMP phospho-diesterase among analogues of tamoxifen: Correlation with cytotoxicity. Biochem Pharmacol 40: 283?289, 1990","journal-title":"Biochem Pharmacol"},{"key":"CR15","first-page":"6274","volume":"46","author":"A Gulino","year":"1986","unstructured":"Gulino A, Barrera G, Vacca A, Farina Aet al.: Calmodulin antagonism and growth inhibitory activity of triphenylethylene antioestrogens in MCF-7 human breast cancer cells. Cancer Res 46: 6274?6278, 1986","journal-title":"Cancer Res"},{"key":"CR16","first-page":"2398","volume":"49","author":"EA Musgrove","year":"1989","unstructured":"Musgrove EA, Wakeling AE, Sutherland RL: Points of action of oestrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res 49: 2398?2404, 1989","journal-title":"Cancer Res"},{"key":"CR17","first-page":"608","volume":"54","author":"Nolvadex Adjuvant Trial Organisation","year":"1987","unstructured":"Nolvadex Adjuvant Trial Organisation: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 54: 608?611, 1987","journal-title":"Br J Cancer"},{"key":"CR18","first-page":"171","volume":"ii","author":"Medical Research Council Scottish Trials Office","year":"1988","unstructured":"Medical Research Council Scottish Trials Office: Adjuvant tamoxifen in the management of operable breast cancer. Lancet ii: 171?175, 1988","journal-title":"Lancet"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0140-6736(92)90997-H","volume":"339","author":"Early Breast Cancer Trialists Collaborative Group","year":"1992","unstructured":"Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1?15 and 71-75, 1992","journal-title":"Lancet"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/0959-8049(92)90445-8","volume":"28","author":"MD Brooks","year":"1992","unstructured":"Brooks MD, Ebbs SR, Colletta AA, Baum M: Desmoid tumours treated with triphenylethylenes. Eur J Cancer 28: 1014?1018, 1992","journal-title":"Eur J Cancer"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/bjc.1990.307","volume":"62","author":"AA Colletta","year":"1990","unstructured":"Colletta AA, Wakefield LM, Howell FV, Roozendaal KEP, Danielpour D, Ebbs SR, Sporn MB, Baum M: Anti-oestrogens induce the secretion of active transforming growth factor beta from human foetal fibroblasts. Br J Cancer 62:405?409, 1990","journal-title":"Br J Cancer"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S0140-6736(87)92206-9","volume":"i","author":"JA Haggie","year":"1987","unstructured":"Haggie JA, Sellwood RA, Howell A, Birch JM, Schor SL: Fibroblasts from relatives of patients with hereditary breast cancer show foetal-like behaviourin vitro. Lancet i: 1455?1457, 1987","journal-title":"Lancet"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ijc.2910370606","volume":"37","author":"SL Shor","year":"1986","unstructured":"Shor SL, Haggie JA, Durning P, Howell A, Smith L, Sellwood RA, Crowther D: Occurrence of a foetal fibroblast phenotype in familial breast cancer. Int J Cancer 37: 831?836, 1986","journal-title":"Int J Cancer"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1210\/mend-4-1-46","volume":"4","author":"AB Glick","year":"1990","unstructured":"Glick AB, Danielpour D, Morgan D, Sporn MB, Yuspa SH: Induction and autocrine receptor binding of TGF-?2 during terminal differentiation of primary mouse keratinocytes. Mol Endocrinology 4: 46?52, 1990","journal-title":"Mol Endocrinology"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0092-8674(87)90193-0","volume":"48","author":"C Knabbe","year":"1987","unstructured":"Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer. Cell 48: 417?428, 1987","journal-title":"Cell"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1172\/JCI114983","volume":"87","author":"AA Colletta","year":"1991","unstructured":"Colletta AA, Wakefield LM, Howell FV, Danielpour D, Baum M, Sporn MB: The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. J Clin Invest 87: 277?283, 1991","journal-title":"J Clin Invest"},{"key":"CR27","first-page":"4261","volume":"52","author":"A Butta","year":"1992","unstructured":"Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, MacKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta AA: Induction of transforming growth factor beta in human breast cancerin vivo following tamoxifen treatment. Cancer Res 52: 4261?4262, 1992","journal-title":"Cancer Res"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/0277-5379(89)90308-8","volume":"25","author":"JL Mansi","year":"1989","unstructured":"Mansi JL, Smith IE, Walsh G, A'Hern RP, Harmer C, Sinnett HD, Trott PA, Fisher C, McKinna JA: Primary medical therapy for operable breast cancer. Eur J Clin Oncol 25: 1623?1627, 1989","journal-title":"Eur J Clin Oncol"},{"key":"CR29","first-page":"5486","volume":"44","author":"Y Myall","year":"1984","unstructured":"Myall Y, Shiu RPC, Bhaumick B: Receptor binding and growth promoting activity of insulin-like growth factors in human breast cancer cells (T47D) in culture. Cancer Res 44: 5486?5490, 1984","journal-title":"Cancer Res"},{"key":"CR30","first-page":"4083","volume":"48","author":"KP Karey","year":"1988","unstructured":"Karey KP, Sirbasku DA: Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17?-oestradiol. Cancer Res 48: 4083?4092, 1988","journal-title":"Cancer Res"},{"key":"CR31","first-page":"91","volume":"6","author":"KJ Cullen","year":"1992","unstructured":"Cullen KJ, Lippman ME, Chow D, Hill S, Rosen N, Zwiebel JA: Insulin-like growth factor-II over-expression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinology 6: 91?100, 1992","journal-title":"Mol Endocrinology"},{"key":"CR32","first-page":"48","volume":"50","author":"KJ Cullen","year":"1990","unstructured":"Cullen KJ, Yee D, Sly WSet al.: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50: 48?53, 1990","journal-title":"Cancer Res"},{"key":"CR33","first-page":"1343","volume":"48","author":"F Pekonen","year":"1988","unstructured":"Pekonen F, Paranen S, Makinen T, Rutanen E-M: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48: 1343?1347, 1988","journal-title":"Cancer Res"},{"key":"CR34","first-page":"6429","volume":"48","author":"JP Peyrat","year":"1988","unstructured":"Peyrat JP, Bonneterre J, Beuscart R, Djianne J, Demaille A: Insulin-like growth factor I receptors in human breast cancer and their relation to oestradiol and progesterone receptors. Cancer Res 48: 6429?6433, 1988","journal-title":"Cancer Res"},{"key":"CR35","first-page":"6691","volume":"48","author":"D Yee","year":"1988","unstructured":"Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schwartz A, Lippman ME, Rosen N: Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48: 6691?6696, 1988","journal-title":"Cancer Res"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1210\/mend-3-3-509","volume":"3","author":"D Yee","year":"1989","unstructured":"Yee D, Paik S, Lebovic G, Marcus R, Favoni R, Cullen KJ, Lippman ME, Rosen N: Analysis of IGF I gene expression in malignancy. Evidence for a paracrine role in human breast cancer. Mol Endocrinol 3: 509?517, 1989","journal-title":"Mol Endocrinol"},{"key":"CR37","first-page":"4978","volume":"51","author":"KJ Cullen","year":"1991","unstructured":"Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME: Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 51: 4978?4985, 1991","journal-title":"Cancer Res"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF01833337","volume":"22","author":"M Pollak","year":"1992","unstructured":"Pollak M, Huynh HT, Pratt Lefebvre S: Tamoxifen reduces serum insulin-like growth factor I (IGF I). Breast Cancer Research and Treatment 22: 91?100, 1992","journal-title":"Breast Cancer Research and Treatment"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0006-291X(88)81338-X","volume":"153","author":"ML Stracke","year":"1988","unstructured":"Stracke ML, Kohn EC, Aznavoorian SA, Wilson LL, Salomon D, Krutzsch HC, Liotta LA, Schiffmann E: Insulin-like growth factors stimulate chemotaxis in human melanoma cells. Biochem Biophys Res Comm 153: 1076?1083, 1988","journal-title":"Biochem Biophys Res Comm"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/jnci\/84.12.966","volume":"84","author":"M Pollak","year":"1992","unstructured":"Pollak M, Sem AW, Richard M, Tetenes E, Bell R: Inhibition of metastatic behaviour of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 84: 966?971, 1992","journal-title":"J Natl Cancer Inst"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1210\/endo.130.6.1350760","volume":"130","author":"GS Tannenbaum","year":"1992","unstructured":"Tannenbaum GS, Gurd W, Lapointe M, Pollak M: Tamoxifen attenuates pulsatile growth hormone secretion: Mediated in part by somatostatin. Endocrinology 130: 3395?3402, 1992","journal-title":"Endocrinology"},{"key":"CR42","first-page":"1727","volume":"53","author":"HT Huynh","year":"1993","unstructured":"Huynh HT, Tetenes E, Wallace L, Pollak M:In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res 53: 1727?1730, 1993","journal-title":"Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00689672.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00689672\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00689672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T14:40:55Z","timestamp":1554820855000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00689672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1994]]}},"alternative-id":["BF00689672"],"URL":"https:\/\/doi.org\/10.1007\/bf00689672","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994]]}}}